✦ LIBER ✦

Adjuvant anthracycline in breast cancer. Improved outcome in premenopausal patients following substitution of methotrexate in the CMF Combination with epirubicin

✍ Scribed by Henning T. Mouridsen; Jørn Andersen; Michael Andersson; Per Dombernowsky; Bent Ejlertsen; Carsten Rose; Peter G. Sørensen; Erik Sandberg; Knud W. Andersen; Maj-Britt Jensen; Nils O. Bengtson; Jonas Bergh; Bo Nordenskjöld

Book ID: 117667254
Publisher: Elsevier Science
Year: 1999
Tongue: English
Weight: 118 KB
Volume: 35
Category: Article
ISSN: 0959-8049
DOI: 10.1016/s0959-8049(99)80704-7

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Improved outcome from substituting metho

Improved outcome from substituting methotrexate with epirubicin: Results from a randomised comparison of CMF versus CEF in patients with primary breast cancer

✍ Bent Ejlertsen; Henning T. Mouridsen; Maj-Britt Jensen; Jørn Andersen; Søren Col 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 229 KB

Incidence of chemotherapy-induced amenor

Incidence of chemotherapy-induced amenorrhea in premenopausal patients with breast cancer following adjuvant anthracycline and taxane

✍ Yuko Okanami; Yoshinori Ito; Chie Watanabe; Kotaro Iijima; Takuji Iwase; Nahomi 📂 Article 📅 2011 🏛 Springer Japan 🌐 English ⚖ 229 KB

Randomized phase III trial of adjuvant e

Randomized phase III trial of adjuvant epirubicin followed by cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) versus CMF followed by epirubicin in patients with node-negative or 1–3 node-positive rapidly proliferating breast cancer

✍ Dino Amadori; Rosella Silvestrini; Mario De Lena; Francesco Boccardo; Andrea Roc 📂 Article 📅 2010 🏛 Springer US 🌐 English ⚖ 485 KB

Optimal delivery of anthracycline-based

Optimal delivery of anthracycline-based chemotherapy in the adjuvant setting improves outcome of breast cancer patients

✍ Isabel Chirivella; Begoña Bermejo; Amelia Insa; Alejandro Pérez-Fidalgo; Ana Mag 📂 Article 📅 2008 🏛 Springer US 🌐 English ⚖ 252 KB

Dose-intensified epirubicin versus stand

Dose-intensified epirubicin versus standard-dose epirubicin/cyclophosphamide followed by CMF in breast cancer patients with 10 or more positive lymph nodes: Results of a randomised trial (GABG-IV E-93) – The German Adjuvant Breast Cancer Group

✍ Wolfgang Eiermann; Erika Graf; Beyhan Ataseven; Bettina Conrad; Jörn Hilfrich; H 📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 665 KB

The association of HER-2 status with dis

The association of HER-2 status with disease outcome in premenopausal early breast cancer patients treated with adjuvant ovarian ablation

✍ S. Susnjar; T. Vujasinovic; Z. Abu Rabi; D. Gavrilovic; Z. Neskovic-Konstantinov 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 57 KB